In a 2-year clinical trial of relapsing MS patients, 627 people were treated with TYSABRI versus 315 with placebo. TYSABRI decreased the number of relapses by 67% compared with placebo (TYSABRI 0.22 vs placebo 0.67).
In addition to the clinical trial for TYSABRI, it was further studied in the ongoing TYSABRI Observational Program (TOP). We now have the 10-year interim results.
This analysis studied the long-term safety and efficacy effects of TYSABRI in 6,148 patients with relapsing multiple sclerosis. These patients took 300 mg of TYSABRI every 4 weeks.
NO NEW SAFETY CONCERNS WERE IDENTIFIED
PEOPLE TAKING TYSABRI HAD APPROXIMATELY
reduction in average number of relapses per year*, which remained consistent through all
9 years of the study.
*Compared to average number of relapses in the year before they started TYSABRI (1.99 vs 0.24).